In June 2023, the FDA issued a warning that unapproved versions of GLP-1 drugs "can be risky for patients, as unapproved versions do not undergo FDAs review for safety, effectiveness and quality before they are marketed." The GLP-1 drug market has been dominated by pharmaceutical giant Novo Nordisk
Separate products give independent dose control
[1][2] Selective Receptor Interaction: Its high selectivity allows researchers to investigate targeted receptor activation without broad endocrine interference
To view or add a comment, sign in Understanding oral drug response requires bridging the complex biological interactions occurring across the gastrointestinal tract
Current treatments primarily focus on rapid cooling and organ support
Ectopic or aberrant congenital dermal melanocytoses, which occur at sites other than the lumbosacral area, are most common on the extremities, upper back or chest, may be particularly large or deeply pigmented and are less likely to resolve
